Moderna (MRNA) has maxed out on its manufacturing capacity for 2021 and has shifted its focus to 2022 and 2023 advanced purchasing orders for its COVID-19 vaccine, officials said Thursday. The company reported $2.8 billion in vaccine revenue for the second quarter and anticipates pricing of doses will fall and impact revenue as more low- and middle-income countries become the dominant purchasers, according to officials on an earnings call. In addition, Moderna expects the global pandemic to… Source link
Read More »Countries, not manufacturers, are responsible for WHO moratorium on boosters
